3RD-GENERATION CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELLS (CARTS) FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - UPDATE ON THE ONGOING ACADEMIC PHASE 1/2 TRIAL (HD-CAR-1)

被引：0
|
作者：
Derigs, P. [1 ]
Kunz, A. [1 ]
Dreger, P. [1 ]
Schmitt, A. [1 ]
Schubert, M. -L. [1 ]
Brueggemann, M. [2 ]
Bernhard, H. [3 ]
Kobbe, G. [4 ]
Lindemann, A. [5 ]
Rummel, M. [6 ]
Wang, L. [1 ]
Michels, B. [1 ]
Waldhoff, P. [1 ]
Korell, F. [1 ]
Laier, S. [7 ]
Ho, A. D. [1 ]
Mueller-Tidow, C. [1 ]
Schmitt, M. [1 ]
机构：
[1] Univ Hosp Heidelberg, Dept Internal Med 5, Heidelberg, Germany
[2] Univ Hosp Schleswig Holstein, Dept Internal Med 2, Kiel, Germany
[3] Klinikum Darmstadt, Dept Internal Med 5, Darmstadt, Germany
[4] Univ Hosp Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[5] Onkol Ettlingen, Praxis Onkol, Ettlingen, Germany
[6] Univ Hosp Giessen, Dept Internal Med 4, Giessen, Germany
[7] German Red Cross Drk Blood Donat Serv Baden Wurtt, Inst Clin Transfus Med & Cell Therapy IKTZ, Heidelberg, Germany
来源：
HUMAN GENE THERAPY | 2023年 / 34卷 / 21-22期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P003
引用
收藏
页码：A7 / A8
页数：2
相关论文
共 50 条
  • [21] A phase I trial of CD19-targeted EGFRt/19-28z/4-1BBL armored chimeric antigen receptor (CAR) modified T cells in patients with relapsed or refractory chronic lymphocytic leukemia.
    Park, Jae Hong
    Riviere, Isabelle
    Wang, Xiuyan
    Senechal, Brigitte
    Bernal, Yvette
    Halton, Elizabeth
    Diamonte, Claudia
    Wang, Yongzeng
    Brentjens, Renier J.
    Sadelain, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/ refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression
    Danylesko, Ivetta
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Jacoby, Elad
    Toren, Amos
    Shouval, Roni
    Itzhaki, Orit
    Avigdor, Abraham
    Shimoni, Avichai
    Nagler, Arnon
    CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, 2024, 72 (04)
  • [23] ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Kenderian, Saad S.
    Flinn, Ian W.
    Hill, Brian T.
    Maris, Michael
    Ghia, Paolo
    Byrne, Michael
    Bartlett, Nancy L.
    Pagel, John M.
    Zheng, Yan
    Kanska, Justyna
    Zhang, Wangshu
    Masouleh, Behzad Kharabi
    Granados, Enrique
    Ibarz, Javier Pinilla
    BLOOD, 2022, 140 : 7454 - 7456
  • [24] Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)-expressing T cells
    Mikhailova, Ekaterina
    Illarionova, Olga
    Shelikhova, Larisa
    Zerkalenkova, Elena
    Molostova, Olga
    Olshanskaya, Yulia
    Novichkova, Galina
    Maschan, Alexey
    Maschan, Michael
    Popov, Alexander
    HAEMATOLOGICA, 2022, 107 (04) : 970 - 974
  • [25] A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+chronic lymphocytic leukemia (CLL).
    Porter, David L.
    Frey, Noelle V.
    Loren, Alison W.
    Levine, Bruce
    Kalos, Michael
    McConville, Holly
    Gilmore, Joan
    Chew, Anne
    Shen, Angela
    So, Charlene
    Sharr, Michele
    Wood, Patricia Ann
    June, Carl H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL
    Porter, David L.
    Frey, Noelle V.
    Melenhorst, Jan J.
    Hwang, Wei-Ting
    Lacey, Simon F.
    Shaw, Pamela A.
    Chew, Anne
    Marcucci, Katherine
    Gill, Saar
    Loren, Alison W.
    Mato, Anthony R.
    Schuster, Stephen J.
    Lledo, Lester
    McConville, Holly
    Gilmore, Joan
    Capobianchi, James
    Kalos, Michael D.
    Grupp, Stephan A.
    Levine, Bruce
    June, Carl H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Phase 1 Results of CNCT19: CD19 CAR Constructed of a New Anti-CD19 Chimeric Antigen Receptor in Relapsed or Refractory Acute Lymphoblastic Leukemia
    Gu, Runxia
    Liu, Fang
    Zou, Dehui
    Liu, Bingcheng
    Liu, Wei
    Chen, Xiaojuan
    Liu, Kaiqi
    Guo, Ye
    Gong, Xiaoyuan
    Lv, Rui
    Chen, Xia
    Zhou, Chunlin
    Zhong, Mengjun
    Xu, Yingxi
    Wang, Huijun
    Wei, Hui
    Mi, Yingchang
    Qiu, Lugui
    Lv, Lulu
    Wang, Min
    Wang, Ying
    Zhu, Xiaofan
    Wang, Jianxiang
    BLOOD, 2019, 134
  • [28] Efficacy of anti-CD19 chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphocytic leukemia in a multicenter trial.
    Xiao, Lei
    Huang, He
    Huang, Xiaojun
    Ke, Xiaoyan
    Hu, Yu
    Li, Junmin
    Zhang, Qing
    Hu, Yongxian
    Jiang, Qian
    Hu, Jiang
    Jing, Hongmei
    Zhang, Xiaohong
    Wu, Zhao
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+Lymphomas
    Schuster, Stephen J.
    Svoboda, Jakub
    Nasta, Sunita Dwivedy
    Porter, David L.
    Chong, Elise A.
    Mahnke, Yolanda
    Lacey, Simon F.
    Melenhorst, J. Joseph
    Chew, Anne
    Shah, Gaurav
    Hasskarl, Jens
    Litchman, Manuel
    Wasik, Mariusz A.
    Landsburg, Daniel J.
    Mato, Anthony R.
    Garfall, Alfred L.
    Frey, Noelle V.
    Marcucci, Katherine T.
    Shea, Joanne
    McConville, Holly
    Zheng, Zhaohui
    Levine, Bruce L.
    June, Carl H.
    BLOOD, 2014, 124 (21)
  • [30] Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+lymphomas.
    Schuster, Stephen J.
    Svoboda, Jakub
    Nasta, Sunita
    Porter, David L.
    Mato, Anthony
    Shah, Gaurav D.
    Landsburg, Daniel Jeffrey
    Chong, Elise A.
    Lacey, Simon F.
    Melenhorst, Jan J.
    Chew, Anne
    Hasskarl, Jens
    Shah, Nirav Niranjan
    Wasik, Mariusz A.
    Marcucci, Katherine
    Zheng, Zhaohui
    Levine, Bruce
    June, Carl H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345